Trinity Capital Boosts Elucent Medical's Growth with $30 Million Investment

Trinity Capital Inc. (NASDAQ: TRIN), a leading international alternative asset manager, has announced a significant $30 million growth capital investment in Elucent Medical, a pioneering medical technology company transforming the field of surgical guidance. This strategic partnership will enable Elucent Medical to scale its operations, accelerate innovation, and solidify its position as a market leader in breast navigation and other soft tissue oncology applications.

Elucent Medical's flagship technologies, EnVisio® and SmartClip®, offer precision In-Site Spatial Intelligence during oncologic procedures, enhancing surgical accuracy and efficacy. The company's groundbreaking solutions have already made a significant impact on the market, with Elucent ranked #7 on the 2023 Inc. 5000 list and #6 in 2024, reflecting its rapid growth and market potential.

The $30 million investment from Trinity Capital will further propel Elucent Medical's growth trajectory, enabling the company to:

1. Expand its coverage area and refine its care model, making its innovative technologies more accessible to healthcare providers and patients.
2. Accelerate its innovation and commercialization efforts, driving revenue growth and market expansion.
3. Strengthen its financial position, providing a solid foundation for future growth and success.

Trinity Capital's investment in Elucent Medical demonstrates the growing interest in and validation of the company's transformative approach to surgical guidance. The partnership aligns with Trinity Capital's mission to provide investors with stable and consistent returns through access to the private credit market, while supporting innovative, growth-oriented companies like Elucent Medical.

Elucent Medical's CEO, Jason Pesterfield, expressed enthusiasm about the partnership, stating, "Our EnVisio® System gives surgeons confidence before, during, and after their surgical procedures so they know they have delivered unparalleled accuracy and precision for their patients. We are in scale mode and are excited to partner with Trinity Capital."

Trinity Capital's Managing Director, Life Sciences, Lauren Cosentino, echoed Pesterfield's sentiment, commenting, "Elucent is disrupting the field of surgical guidance with its cutting-edge technology. We are thrilled to be a part of Elucent's journey as they continue to innovate and improve surgical outcomes."

In conclusion, Trinity Capital's $30 million investment in Elucent Medical is a strategic move that will drive growth, innovation, and market leadership for the pioneering medical technology company. The partnership aligns with both companies' missions and values, positioning them for continued success in the rapidly evolving healthcare technology sector.